BENITIONSClinical Trial Intelligence

Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain

不适用 已完成 NCT02822989

适应症Lupus Erythematosus, Systemic, Musculoskeletal Pain
分期不适用
申办方Northwell Health
状态已完成
受试者人数19 人
干预(药物)Vagus nerve stimulation, Sham vagus nerve stimulation
开始日期2017年11月1日
完成日期2018年4月30日
结果公布日2026年7月8日

摘要

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms. This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain. This study will additionally investigate the biologic effects of vagus nerve stimulation on inflammation. It will be the first clinical study using one of the body's own pathways of modulating the immune system and inflammatory response, the cholinergic anti-inflammatory pathway, in SLE.

Change in Musculoskeletal Pain From Baseline.

5 days · units on a scale

Vagus Nerve Stimulation-5.00 units on a scale
Sham Vagus Nerve Stimulation0.10 units on a scale

Percentage of Subjects With Treatment Emergent Adverse Events.

12 days · Participants

Vagus Nerve Stimulation1 Participants
Sham Vagus Nerve Stimulation0.00 Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。